Search
Contact
04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion of an exclusive pharmaceutical licensing agreement for the G-dase-E®-CRISPR-Cas technology with Akribion Therapeutics.

BRAIN Biotech has entered into an agreement with Royalty Pharma for the monetization of the license rights to the investigational pharmaceutical compound deucrictibant in the amount of up to EUR 128.88 million. BRAIN Biotech will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestone payments of up to EUR 18.42 million and additional potential long-term sales-related milestones of up to EUR 92.05 million. In addition, BRAIN Biotech has entered into an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the genome editing nuclease G-dase E® for the pharmaceutical sector. BRAIN Biotech will receive up to EUR 92.3 million in R&D and commercial milestone payments from Akribion for the granting of these exclusive rights for use in the pharmaceutical field. In addition, BRAIN Biotech will be entitled to royalties from future net sales. The payment structure is based on progress in clinical development and future commercialization success. KPMG Law provided comprehensive legal advice on the structuring of the transaction, including all aspects of copyright, licensing and transaction law. The accounting and tax advice as well as the comprehensive valuation of the licenses was provided by a KPMG team. Royalty Pharma was advised by an international team from Goodwin Procter. Advisor Brain Biotech AG:

KPMG Law Rechtsanwaltsgesellschaft mbH: Stefan Kimmel (Partner, Corporate/M&A, Berlin), Dr. Anna Wipper (Partner, IP/IT, Berlin) – both lead – Gunars Urdze (Senior Manager, Corporate, M&A, Cologne), Dr. Thomas Beyer (Senior Manager, IP/IT, Berlin), Isabelle Knoché (Senior Manager, Legal Financial Services, Frankfurt/Main), Christina Laux (Senior Associate , Legal Financial Services, Frankfurt/Main),; Dr. Jonas Brueckner (Partner, Antitrust and Foreign Trade Law, Berlin).

KPMG AG Wirtschaftsprüfungsgesellschaft: Christian Klingbeil (Partner, Valuation, Head of Deal Advisory Life Science, Munich), Sebastian Bongartz (Senior Manager, International Transaction Tax, Düsseldorf).

 

Explore #more

26.11.2025 | KPMG Law Insights

EU deforestation regulation forces companies to act

Anyone who trades in or uses the raw materials soy, oil palm, cattle, coffee, cocoa, rubber and wood and certain products made from them should…

25.11.2025 | KPMG Law Insights

Special infrastructure assets: how the administration manages to implement projects quickly

The special infrastructure fund creates the opportunity to catch up on years of investment backlog. There is a need for urgency. Defence capability, economic growth…

21.11.2025 | In the media

KPMG Law Interview in Real Estate I Haufe: Substitute building materials: “Secondary is not second class”

The Substitute Building Materials Ordinance is intended to harmonize the circular economy in construction, but legal uncertainty and bureaucracy are holding it back. How can…

21.11.2025 | KPMG Law Insights

Residential construction turbo: more living space on existing properties

Since October 30, 2025, new regulations on the creation of living space have been in force in the German Building Code (BauGB). At the heart…

19.11.2025 | KPMG Law Insights

New Packaging Implementation Act tightens obligations for companies

With a new Packaging Implementation Act (VerpackDG), German law is to be adapted to the EU Packaging Regulation. The Federal Ministry for the Environment…

18.11.2025 | In the media

KPMG Law Statement in the FAZ on the subject of deepfakes

Fraudsters can easily falsify invoices or even act as company bosses. Companies can defend themselves against this, but there are no miracle weapons against AI…

17.11.2025 | KPMG Law Insights

Video surveillance in rental properties: What should landlords be aware of?

Video surveillance of rented properties is only possible under strict legal conditions. More and more owners want to keep an eye on and secure their…

13.11.2025 | KPMG Law Insights

Implementing AI in the legal department – these are the success factors

Artificial intelligence (AI) only benefits the legal department if it is implemented correctly. The technology promises to automate time-consuming routine work and fundamentally improve the…

13.11.2025 | KPMG Law Insights

First omnibus package to relax CSDDD, CSRD and EU taxonomy obligations

On November 13, 2025, the EU Parliament voted on its negotiating position regarding the so-called omnibus package, which provides for a relaxation of the CSRD,…

12.11.2025 | In the media

KPMG Law Statement in In-house Counsel: More stability under the umbrella of corporate governance

There is a lot of talk about “corporate governance” in the face of multiple crises and regulatory tendencies on the part of legislators. But what…

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll